Founded in 2012, Opterion Health is a research-driven Swiss company focused on developing a novel peritoneal dialysis (PD) solution. Their goal is to enhance the well-being of patients and their loved ones by offering flexibility at work and home, while also reducing dialysis-related healthcare costs. With a glucose-free PD solution, they address metabolic challenges and provide a valuable option for diabetic dialysis patients. Privately held and financed by Angel Investors, Opterion Health's approach involves improving the osmotic driver and enhancing biocompatibility, aiming to increase the medical utility of PD. This innovation marks the first significant advancement in PD in the last two decades.